David E. Lazar - 21 Oct 2025 Form 4 Insider Report for NovaBay Pharmaceuticals, Inc. (NBY)

Reporting relationship: 10%+ Owner
Issuer ticker: NBY
Reported as of: 21 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jan 2026, 19:30:12 UTC
Prior SEC filing: 17 Oct 2025
Next SEC filing: 02 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ David E. Lazar

Key filing fact

David E. Lazar filed Form 4 for NovaBay Pharmaceuticals, Inc. (NBY) on 29 Jan 2026.

Key facts

This page summarizes David E. Lazar's Form 4 filing for NovaBay Pharmaceuticals, Inc. (NBY).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Jan 2026, 19:30.

Change

Previous filing in this sequence was filed on 17 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001932843 Primary reporting owner

Lazar David E.

Relationship: 10%+ Owner
Address: 44, TOWER 100, THE TOWERS, WINSTON CHURCHILL, PAITILLA, PANAMA CITY, PANAMA
Signature: /s/ David E. Lazar
Signature date: 29 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBY transaction

Common Stock

Award

Transaction value
Shares: +6,388,000
Change %
Price
Shares after: 6,388,000
Date: 21 Oct 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBY transaction Derivative

Series D Convertible Preferred Stock

Options Exercise

Transaction value
Shares: -39,925
Change %: -100%
Price
Shares after: 0
Date: 21 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,388,000
Exercise price
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David E. Lazar is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

The shares of Common Stock reported herein were issued upon the automatic conversion of the Series D Preferred Stock held by the Reporting Person three business days after the annual meeting of stockholders (the "Annual Meeting") of NovaBay Pharmaceuticals, Inc. (the "Issuer"), which occurred on October 16, 2025.

Footnote F2

The shares of Series D Preferred Stock are convertible at the option of the Reporting Person for no additional consideration. Each share of Series D Preferred Stock is convertible into 160 shares of the Issuer's Common Stock at any time, subject to certain ownership limitations.

Footnote F3

The Series D Preferred Stock is exercisable immediately upon issuance, is perpetual and has no expiration date.

Footnote F4

On October 9, 2025, David E. Lazar (the "Reporting Person") entered into a Securities Purchase Agreement pursuant to which the the Reporting Person sold all of his title and interest in (i) an aggregate of 441,325 shares of Series D Preferred Stock for $9,850,000 and (ii) the rights and obligations to purchase 268,750 shares of Series E Preferred Stock for an additional $2,150,000 payable to the Issuer (the "October Transaction"). The closing of the October Transaction occurred on October 16, 2025 following the Issuer's Annual Meeting. Following the October Transaction, the Reporting Person retained 39,925 shares of Series D Preferred Stock, which automatically converted into shares of hte Issuer's Common Stock three business days after the Annual Meeting.

SEC remarks

The filing of this Form 4 constitutes an exit filing for the Reporting Person.